FIG 2.

HIV-1-infected cells expressing TRIM5 variants enhance CD8⁺ T-cell activation. (A) Frequency of GFP⁺ cells in EV-, RhT5-, and TCyp-expressing cells in the presence or absence of 5 μM SmBz-CsA or CsA. The SmBz-CsA molecule is shown above the graph. Data are shown as the mean ± standard error of the mean from three independent experiments performed in triplicate. (B) Frequency of CD107a/MIP-1β expression in HIV-1-specific CD8⁺ T cells cocultured in response to EV, RhT5, and TCyp and in a B-cell line (BCl) loaded with cognate peptide. The data are from two independent experiments performed in duplicate. (C) Representative zebra plot of the frequency of CD107a/MIP-1β expression in HIV-1 Gag- or Pol-specific CD8⁺ T cells in coculture with infected cells expressing RhT5 in the presence or absence of SmBz-CsA or CsA. (D) Activation levels were measured by the frequency of CD107a/MIP-1β in HIV-1 Gag-specific CD8⁺ T cells cocultured with RhT5- or TCyp-expressing cells infected with HIV-1 in the presence or absence of AZT, SmBz-CsA, or CsA. (E) Activation levels were measured by the frequency of CD107a/MIP-1β in Pol-specific CD8⁺ T cells cocultured with RhT5- or TCyp-expressing cells infected with HIV-1 in the presence or absence of AZT, SmBz-CsA, or CsA. (F) Representative zebra plot showing CD107a/MIP-1β expression in HIV-1 Gag- or Pol-specific CD8⁺ T cells in response to peptide pulse control B cells loaded with cognate peptide. The P values were calculated using a Mann-Whitney test. Only significant values are represented (***, P < 0.0001; **, P < 0.001; *, P < 0.01). Experiments shown in panel A and in panels C to E were performed at an MOI of 0.2.